TokenPost topic
Biotechnology
86 TokenPost stories are tagged Biotechnology. The newest appear first.
Latest Biotechnology stories
- AbbVie Agrees to Pay Up to $2.54 Billion in DISCO Pharmaceuticals Collaboration
The companies will collaborate on developing novel cancer treatments, expanding AbbVie’s work in next-generation therapies.
· Business
- SELLAS Prices $150 Million Stock Offering at $13 a Share
The offering covers 11.54 million common shares, with gross proceeds expected to total $150 million before discounts, commissions and other expenses.
· Business
- Three Drugmakers’ Shares Gain After White House Withdraws FDA Nominee
The nomination was for Dr. Heidi Overton to lead the Food and Drug Administration. The three companies have separate FDA matters at different stages.
· Regulation
- Moderna Shares Fall 3.9% to $206.80 on Tuesday, Nov. 17
The stock lost $8.47, with 8,277,036 shares traded; the close came at 4 p.m. ET (21:00 UTC).
· Investing
- CytomX to Receive $5 Million From Regeneron for Cancer Drug Milestone
The payment is tied to a preclinical milestone in the companies’ cancer drug development partnership.
· Business
- Palatin Targets First-Half 2027 Start for Lead Lipidated MC4R Peptide
Fiscal 2027 first-quarter priorities included IND-enabling activities for the peptide and development of oral small-molecule candidates.
· Business
- Instil Bio Posts $0.62 GAAP Loss Per Share, $0.48 Non-GAAP Loss Per Share
Instil Bio expects its $67.1 million in cash, cash equivalents, restricted cash, marketable securities and long-term investments to fund its operating plan through 2027.
· Business
- Moleculin Biotech Cuts Third-Quarter Net Loss 74% to $6.5 Million
Research and development expenses increased 20% to $4.5 million. The company had $7.3 million in cash and cash equivalents at Sept. 30, 2026.
· Business
- Larimar Therapeutics Estimates $128.7 Million in Cash at Quarter-End
The preliminary, unaudited estimate covers cash, equivalents and marketable securities as of Sept. 30, 2026. Larimar projects its cash runway into late Q2 2027.
· Business
- Eli Lilly to Buy Calytrix Bio in All-Cash Deal Worth Up to $1.5 Billion
Calytrix Bio is a privately held biotechnology company, and the transaction is structured as an all-cash deal.
· Business
- Zymeworks Sets $200 Million Limit for Second 2026 Buyback Program
The company expects about $140 million in repurchases through 2028 and plans to begin buying shares before year-end.
· Business
- Appili Therapeutics Posts C$3.5 Million First-Half Net Loss
The loss widened C$1.3 million from a year earlier as the company shifted toward dual-use medical technologies and disclosed C$1.2 million in related-party advances.
· Business
- Crescent Biopharma Posts $37.7 Million Q3 Loss as R&D Costs Rise
The net loss widened from $24.607 million a year earlier, while the per-share loss narrowed to $0.90. Crescent had $289.4 million in cash at quarter-end.
· Business
- Lineage Cell Therapeutics Adds HUNT1, Projects Funding Into Q2 2028
The company reported $45.2 million in cash, cash equivalents and marketable securities. HUNT1 is an enrolling Phase Ib/IIa program for Huntington’s disease.
· Business
- Fractyl Projects $8 Million in Quarterly Operating Cash Spending by Q2 2027
Fractyl had $31.5 million in cash at quarter-end and expects additional capital will be needed to bring Revita to market.
· Business
- Bolt Biotherapeutics Posts Q3 GAAP Loss of $2.25 Per Share
The Nasdaq-listed company trades under the symbol BOLT.
· Business
- Pelthos Targets Xepi Promotion to Current Customers by End of Q1 2027
The company has a separate first-quarter 2027 target for Xepi’s launch. Its proposed merger with Castle Creek Biosciences is expected to close by the end of the quarter, pending approval and other conditions.
· Business
- Twist Bioscience Targets Up to $560 Million in FY2027 Revenue
The forecast includes $100 million from AI drug discovery and positive adjusted EBITDA for the full fiscal year.
· Business
- Absci Eyes December Hair-Loss Data, Reaffirms Mid-2027 Endometriosis Trial Target
The company expects interim 13-week proof-of-concept findings for ABS-201 in December, followed by full 26-week data in early 2027.
· Business
- Taysha Gene Therapies Posts Third-Quarter 2026 Loss of $0.10 Per Share
The net loss per common share was the same on a basic and diluted basis.
· Business
- PepGen Prices 25 Million Shares at $5 in $125 Million Offering
The clinical-stage biotech expects $125 million in gross proceeds before underwriting discounts, commissions and offering expenses. Underwriters have a 30-day option to buy up to 3.75 million more shares.
· Business
- Radical Numerics Tests Local Pathogen Screening With Omnii-1
Evaluations found higher recall on labeled proteins and recovery in simulated viral reads, but did not establish AI-engineered pathogen detection or field performance.
· Technology
- Autolus Raises 2026 AUCATZYL Revenue Outlook to at Least $150 Million
Third-quarter net product revenue increased 95% year over year to $41.2 million. Initial BOBCAT data in progressive multiple sclerosis is planned for October 2027.
· Business
- MaxCyte Agrees to Acquire Akron Bio in $151.8 Million Deal
The proposed transaction includes $105 million in cash, shares valued at about $26.8 million and $20 million in guaranteed deferred payments.
· Business
- AstraZeneca Acquires Omniose, Adds Biotech to Its Infectious Disease Unit
Omniose announced the acquisition Tuesday, Nov. 10, and is now a wholly owned AstraZeneca subsidiary.
· Business
- Attovia Therapeutics Posts Third-Quarter GAAP Loss of $0.76 Per Share
The figure covered the three months ended Sept. 30, 2026, on both basic and diluted bases.
· Business
- Xilio Therapeutics Posts $9.98 Million in Q3 2026 Revenue
Collaboration and license revenue was $10.0 million, compared with $19.1 million a year earlier. Net loss per share was $0.30 on both basic and diluted bases.
· Business
- Coya Therapeutics Posts $0.45 Net Loss Per Share in Third Quarter
Collaboration revenue was $234,134 for the quarter ended Sept. 30, 2026.
· Business
- Hemab Records $0.58 Loss Per Share in Third Quarter of 2026
Net loss rose to $27.3 million from $17.1 million a year earlier as operating and research expenses increased.
· Business
- Definium Targets First-Half 2027 NDA for DT120 ODT, Sees Runway Into 2030
Its cash, cash equivalents and short-term investments totaled $1.046848 billion at Sept. 30.
· Business
- Atea Draws $65 Million From Hercules Facility for Hepatitis C Program
The draw came from a facility of up to $200 million. Atea expects its planned operations to be funded into mid-2028.
· Business
- AbCellera Plans 2027 Late-Stage Development for ABCL635
A Phase 2 study found a placebo-adjusted reduction of 5.3 moderate-to-severe hot flashes per day at week four. AbCellera listed more than $890 million in available liquidity as of Sept. 30.
· Business
- Exicure Announces $4.8 Million Agreement to Sell GPC-100 Assets
The package includes intellectual property, clinical and regulatory data, contracts and equipment tied to the program.
· Business
- Bicara Reports Substantial Enrollment in FORTIFI-HN01 Cancer Trial
Bicara expects topline results from an interim analysis in mid-2027 and says its $442.3 million in cash, cash equivalents and marketable securities can fund operations into the first half of 2029.
· Business
- Heron Therapeutics Q3 Net Revenue Falls 7.8% as Net Loss Narrows
Net loss declined to $5 million from $17.5 million a year earlier. CorMedix Therapeutics agreed to acquire substantially all of Heron's assets.
· Business
- KALA BIO, Inc. Narrows Preliminary Q3 Net Loss to About $0.8 Million
Its preliminary nine-month loss fell to about $4 million. Cash and short-term investments totaled about $7 million at Sept. 30.
· Business
- Turn Therapeutics' Third-Quarter Net Loss Widens to $6.2 Million
Its GAAP loss was $0.21 per basic and diluted share, compared with $0.07 a year earlier.
· Business
- Xenon Plans Q1 2027 Azetukalner Study With $1.2 Billion in Cash and Securities
Xenon submitted a new drug application for focal seizures in Q3 2026; topline results from X-NOVA2 are expected in December.
· Business
- OpenAI Introduces 100-Task Benchmark for AI in Wet-Lab Science
BioBasicsBench tests how AI agents interpret experimental evidence, including failed experiments and ambiguous results.
· Technology
- Allogene Targets Year-End 2027 Enrollment in ALPHA3 Study
The company plans a clinical update around midyear, with interim analysis and any unblinding under DSMB oversight.
· Business